TRIM33 and dermatomyositis: Although it is hard to deny that he had nivolumab-associated dermatomyositis with the high anti-TIF1-γ antibody titer, his course, the presence of skin lesions before nivolumab therapy, strongly suggested that the diagnosis was paraneoplastic dermatomyositis.